

	3
()	3
	3
1.	
2.	
3.	
	11
	12
	16
()	23
—	23
	24
1.	
2.	
	27
1.	
2. Placebo	Nocebo
3. “ ” —	
4.	
4.1	
4.2	
4.3	
	39

1992

60

600

()

"

"

"

"

1992

1999

1998

98%

"

"

"

"

()

1992

1998

72 9% 50

62 1%

90%

98%

70%

()

(

)

298

1. 27

1. 25

50

2005

(

)

1.

1. 1.

:

1.1.			
	12,553	3,502	9,051

	12,731	3,554	9,177
	2,005	563	1,442
	6,478	1,501	4,977
	584	174	410
	34,351	9,294 (27.1%)	25,057 (72.9%)

1. 2

50 62.1% 1. 2): 50 50

1.2.		
	50	50
	6,076	6,477
	4,138	8,593
	768	1 237
	1 864	4 614
	180	404
	13 026 (37.9%)	21,325 (62.1%)

1. 3.

(1. 3)

1.3.		
	9,076	3,447
	6,416	6,315
	765	1,240
	4,478	1,990
()	20,735 (61.5%)	12,992 (38.5%)

1. 4.

1. 4

1.4							
	115	371	513	549	435	22	2005
	37	77	116	124	217	13	584
	152	448	629	673	652	35	2589
%	5.9	17.3	24.3	26.0	25.2	1.4	100

2

31, 030 90. 3% 2. 1

() ()

() ()

28, 571 23, 619

82. 7% 4, 616 16. 2% 336

1. 2%

(2. 1) 2, 483 , 6, 772 4, 926

72. 7% 1, 712 25. 3% 133

2. 0% 1 (2. 1) 2. 2

2.1.

		%		%		%		%
	1,370	20.2	1,035	75.5	318	23.3	16	1.2
	1,332	19.7	979	73.5	334	25.1	19	1.4
	1,148	17.0	827	72.0	301	26.2	20	1.7
	597	8.8	436	73.0	144	24.1	17	2.8
	587	8.7	387	66.0	165	28.1	35	6
	512	7.6	374	73.0	133	26.0	5	1.0
	342	5.1	253	74.0	83	24.3	6	1.8
	20*	0.3	14	70.0	6	30	0	0

	275	4.1	209	76.0	62	22.5	4	1.5
	206	3.0	133	64.6	67	32.5	6	2.9
	177	2.6	142	80.2	34	19.2	1	0.6
	118	1.7	69	58.4	47	39.8	2	1.7
()	88	1.3	68	66.0	18	20.5	2	2.3
	6,772	100	4,926	72.7	1,712	25.3	133	2.0

*

2.2.

	10,475	8,118	2,137	220
	11,904	9,921	1,876	107
*	1,899 (5,323)	(4,000)	(1,240)	(83)
	6,192	5,580	603	9
*	584 (1,449)	(926)	(472)	(50)
*	31,030 (34,454*)	28,146*(81.7%)	5,856*(17.0%)	452*(1.3%)

2 3

86.5%

2.3.

	11,222	1,202	129	12,553
	10,649	1,638	444	12,731
	21,871(86.5%)	2,840(11.2%)	573(2.3%)	25,284

%	86.5	11.2	2.3	100
---	------	------	-----	-----

3.

3

3.			
	()		()
	12,650,000	7,170	1,700
	41,700,000	12,731	3,270
	15,240,700	6,327	2,409
	69,590,700	26,228	2653

1.

: () () () ()

2

62.1% 90% 72.9% 50

3.

3.1) 82.7% (16.2%
1.2%
25.3% 72.7% 2.0%

($U=0.50<2.58$ $P>0.01$) (4) 89.72% 88.83%

3.2

" "

98% 70%

" " " "

" "

" " , " "

" "

88

99% (5) 72.3% 98% 61.5% (1.3)

206

137 66.5% 298 12

298

4 70

3. 4

86. 5%

57. 9%

88. 4%

99. 5%

3. 5

2600

3. 6

1. Current Medical Diagnosis and Treatment 2001: Stephen McPhee et al., McGraw Hill/Appleton & Lange

2

<http://zhengjian.org/zj/articles/2002/3/11/14055.html>

70%

50

500

3 5

5

1. 50% (70% $p < 0.0001$ [:])
10%
2. 7 8 (3
5) ()
3. 60
90% (2 3 $p < 0.0001$).
4. 12
50% 20%
($p < 0.0001$)
50%

20% 30%

500

"

" [http: //www.zhengji an. org/zj /art i cl es/2001/1/22/7666. html](http://www.zhengji an. org/zj /art i cl es/2001/1/22/7666. html)

))

" " " "

1.

(Typhoid Mary) (1) (Mary Mallon)

(2)

(7-9) Defensin(3-5) (6)

" "

(Bcl 2 Bcl -xL) (10-12)

2

Proteasome

(13)

(14, 15)

(15-19)

(20,

21)

Proteasome

(22)

1. Marr, J. S. 1999. Typhoid Mary. Lancet 353, no. 9165: 1714.
2. Li, Q, Y. Xia, G. E. Garcia, Q. Chen, P. Li, G. M. Romero, J. A. Lopez, R. J. Johnson, and L. Feng. 2002. Genome-wide profiles of gene expression in neutrophils from Falun Gong practitioners and normal healthy controls. First World Congress of Future Science and Culture.
3. Hughes, A. L. 1999. Evolutionary diversification of the mammalian defensins. Cell Mol Life Sci 56, no. 1-2: 94.

4. Chertov, O., D. Yang, Q.M. Howard, and J.J. Oppenheim. 2000. Leukocyte granule proteins mobilize innate host defenses and adaptive immune responses. *Immunol Rev* 177: 68.
5. Fellermann, K., and E.F. Stange. 2001. Defensins -- innate immunity at the epithelial frontier. *Eur J Gastroenterol Hepatol* 13, no. 7: 771.
6. Samuel, C.E. 2001. Antiviral actions of interferons. *Clin Microbiol Rev* 14, no. 4: 778.
7. Rucker, J., A.L. Edinger, M. Sharron, M. Sanson, B. Lee, J.F. Berson, Y. Yi, B. Margulies, R.G. Collman, B.J. Doranz, M. Parmentier, and R.W. Doms. 1997. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. *J Virol* 71, no. 12: 8999.
8. Hruuk, R., J. Hesselgesser, Y. Zhou, D. Faulds, M. Halks-Miller, S. Harvey, D. Taub, M. Sanson, M. Parmentier, J. Rucker, B.J. Doranz, and R.W. Doms. 1998. The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains. *J Biol Chem* 273, no. 1: 386.
9. Lee, S., H.L. Tiffany, L. King, P.M. Murphy, H. Golding, and M.B. Zaitseva. 2000. CCR8 on human thymocytes functions as a human immunodeficiency virus type 1 coreceptor. *J Virol* 74, no. 15: 6946.
10. Huang, Z. 2000. Bcl-2 family proteins as targets for anticancer drug design. *Oncogene* 19, no. 56: 6627.
11. Gallaher, B.W., R. Hille, K. Raile, and W. Kiess. 2001. Apoptosis: live or die--hard work either way! *Horm Metab Res* 33, no. 9: 511.
12. Adams, J.M., and S. Cory. 2001. Life-or-death decisions by the Bcl-2 protein family. *Trends Biochem Sci* 26, no. 1: 61.
13. Yewdell, J.W. 2001. Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing. *Trends Cell Biol* 11, no. 7: 294.
14. Hershko, A., and A. Ciechanover. 1998. The ubiquitin system. *Annu Rev Biochem* 67: 425.
15. Ciechanover, A., and A.L. Schwartz. 2002. Ubiquitin-mediated degradation of cellular proteins in health and disease. *Hepatology* 35, no. 1: 3.
16. Claverie, J.M. 2001. Gene number. What if there are only 30,000 human genes? *Science* 291, no. 5507: 1255.
17. Vu, P.K., and K.M. Sakamoto. 2000. Ubiquitin-mediated proteolysis and human disease. *Mol Genet Metab* 71, no. 1-2: 261.
18. Adams, J. 2001. Proteasome inhibition in cancer: development of PS-341. *Semin Oncol* 28, no. 6: 613.

19. Shah, S. A., M.W. Potter, and M.P. Callery. 2001. Ubiquitin proteasome pathway: implications and advances in cancer therapy. *Surg Oncol* 10, no. 1-2: 43.
20. Mira, C. V., X. Gong, A. Taylor, R. Villalobos-Molina, and M.M. Scrofano. 1996. Effects of calorie restriction and aging on the expression of antioxidant enzymes and ubiquitin in the liver of Emory mice. *Mech Ageing Dev* 91, no. 2: 115.
21. Scrofano, M.M., F. Shang, T.R. Novell, Jr., X. Gong, D.E. Smith, M. Kelliher, J. Dunning, C.V. Mira, and A. Taylor. 1998. Calorie restriction, stress and the ubiquitin-dependent pathway in mouse livers. *Mech Ageing Dev* 105, no. 3: 273.
22. Garber, K. 2002. Cancer research. Taking garbage in, tossing cancer out? *Science* 295, no. 5555: 612.
23. ,
<http://www.zhengjian.org/zj/articles/2002/3/22/13908.html>

(1-2)
(4-14)

30

30

5

75. 4

(1-2)

(3)

(3)

35-111%

(ATP) ()

2-5 mm x 200-500 um

21

krebs-Hensel ei t

95%

(02) 5%

(002) (14)

3mm

Guth

(13)

800

1

3

7

1 ()

30

30

30

30

" "

1


30

30

5

35

(ATP)



1.

35%

30

30

5

35

1

100


2

1

2

5

35-111%



2


100

3

10

35% 111%

75. 4%



3.

75. 4%

10

1

2

35

111

75. 40 + 17. 34

(ATP) ()

(ATP) ()

30

(
)

?

1. Zhuan Fal un, Li Hongzhi , 1992, <http://www.falundafa.org/book/chi gb/zfl .htm> for Chi nese or <http://falundafa.org/book/eng/zfl us.htm> for Engli sh.
2. Chi na Fal un Gong, Li Hongzhi , 1992,
<http://www.falundafa.org/book/chi gb/fl g.htm> for Chi nese or
<http://falundafa.org/book/eng/fl g.htm> for Engli sh.
3. <http://minghui.ca/> for Chi nese or <http://minghui.ca/eng/> for Engli sh.
4. W Feng, G H Li u, and I. N Pessah. Transmembrane redox sensor of cal ci um release channel ryanodine?receptor. Nature 2000, submitted.

5. W Feng, G H Liu, R H Xia, J.J. Abramson, and I.N. Pessah. Site-selective modification of hyperreactive ?ysteines of ryanodine receptor complex by quinones. *Molec. Pharm* 55: 821-831 (1999).
<http://www.molpharm.org/cgi/content/full/55/5/821>
6. G H Liu, I.N. Pessah. Molecular interaction between ryanodine receptor and glycoprotein triadin involves?redox cycling of functionally important hyperreactive sulfhydryls. *J. Biol. Chem* 269: 33028-33034 (1994).
 Abstract:
[http://128.48.120.7/nw/nw.cgi?sesid=0420627760&Cdiplay\(1,1lon.abs,abbrev\)](http://128.48.120.7/nw/nw.cgi?sesid=0420627760&Cdiplay(1,1lon.abs,abbrev))
7. G H Liu, J.J. Abramson, A.C. Zable, and I.N. Pessah. Direct evidence for existence and functional role of hyperreactive sulfhydryl on ryanodine receptor/triadin Ca²⁺ channel complex selectively labeled by the coumarin maleimide CPM. *Molec. Pharm* 45: 189-200 (1994).
[http://128.48.120.7/nw/nw.cgi?sesid=0420627760&ZS2.2|Cdiplay\(2,1cit.abs,\[CIRG-UCD\]\)](http://128.48.120.7/nw/nw.cgi?sesid=0420627760&ZS2.2|Cdiplay(2,1cit.abs,[CIRG-UCD]))
8. G H Liu and T. Oba. Effects of tetraphenyl boron-induced increase in inner surface charge on Ca²⁺ release channel in sarcoplasmic reticulum *Jpn. J. Physiol.* (1990), 40, 723-736.
[http://128.48.120.7/nw/nw.cgi?sesid=0420627760&ZS5.1|Cdiplay\(1,1cit.abs\)](http://128.48.120.7/nw/nw.cgi?sesid=0420627760&ZS5.1|Cdiplay(1,1cit.abs))
9. G H Liu and T. Oba. Negative surface charges provoke conformational change of membrane proteins and release of calcium from sarcoplasmic reticulum. In "Frontiers in Smooth Muscle Research", Ed. N. Sperelakis and J. D. Wood, Alan R. Liss, Inc., Prog. Clin. Biol. Res. (1990), 327, 779-784. Refer to:
<http://128.48.120.7/nw/nw.cgi.nrb#LB>
10. G H Liu and T. Oba. Change in surface charge of sarcoplasmic reticulum membrane may elicit conformational change in sulfhydryl groups of membrane proteins to release calcium. *Jpn. J. Physiol.* (1989), 39, 412-417.
[http://128.48.120.7/nw/nw.cgi?sesid=0420627760&ZS4.1|Cdiplay\(1,1cit.abs\)](http://128.48.120.7/nw/nw.cgi?sesid=0420627760&ZS4.1|Cdiplay(1,1cit.abs))
11. T. Oba and G H Liu. Chemical modification of sulfhydryl groups inhibits skeletal muscle contraction in frog. In "Frontiers in Smooth Muscle Research", Ed. N. Sperelakis and J. D. Wood, Alan R. Liss, Inc., Prog. Clin. Biol. Res. (1990), 327, 779-784.
 Refer to: <http://128.48.120.7/nw/nw.cgi.nrb#LB>
12. T. Oba, T. Aoki, G H Liu and K. Hotta. A local anesthetic, tetracaine, similarly inhibits Ag⁺ and K⁺ contracture in frog skeletal muscle. *Jpn. J. Physiol.*, 37 (1987), 995-1003.
[http://128.48.120.7/nw/nw.cgi?sesid=0420627760&ZS4.2|Cdiplay\(2,1cit.abs\)](http://128.48.120.7/nw/nw.cgi?sesid=0420627760&ZS4.2|Cdiplay(2,1cit.abs))

13. Guth K and Wojciechowski R (1986) Perfusion cuvette for the simultaneous measurement of mechanical, optical and energetic parameters of skinned muscle fibres. Pflügers Arch Eur J Physiol. 407: 552-557.
[http://128.48.120.7/mw/mw.cgi?sessionId=0420627760&ZS7.7|CVCScs=7&Display\(7,1cit. abs\)](http://128.48.120.7/mw/mw.cgi?sessionId=0420627760&ZS7.7|CVCScs=7&Display(7,1cit. abs))
14. Wang, Y; Xu, Y; Guth, K; Kerrick, W. Troponin C regulates the rate constant for the dissociation of force-generating myosin cross-bridges in cardiac muscle. Journal of Muscle Research and Cell Motility, 1999 Oct, 20(7): 645-53. <http://www.wkap.nl/art.pdf?issn=0142-319&volume=20&page=645>
15. <http://www.zhengjian.org/zj/articles/2002/3/16/14193.html>

()

" "

" "

" "

" "

" [1]

" "

--

" "

"

Substance) Rene Decartes (1596-1650)
Dualism)

Galileo Galilei (1564-1642)

(

"

"

"

"

"

49

"

" (<http://www.zhengjian.org/zj/articles/2002/3/22/13908.html>)

1.

"

"

"

"

"

" "

" [1]

2

" 50

49

" "

()

()

(al ternative and complementary medi ci ne),

()

" " " " " " " "

" "

"

" [2]

"

"

"

"

"

"

"

"

"

"

"

"

"

"

"

"

"

"

"

"

--

--

--

[3]

70~80%

"

"

()

" " "



1. << >>
2. << >>
3. Lawrence M Tierney, Jr., Stephen J. McPhee and Maxine A. Papadakis: Current Medical Diagnosis & Treatment 2001, McGrawhill
4. , MD. , TCMD, MS. , MD. , Ph. D,
,
([http: //zhengj i an. org/zj /arti cl es/2002/3/17/13945. html](http://zhengjian.org/zj/arti cl es/2002/3/17/13945. html))

1.

IHM

IHM

1. 1



A1

A2

A1

" "

" "

A2

" "

" "

1. 2

" " " "

" "

" "



B1

B2

" "

(B1)
(

" "

B2)

1. 3

"

"

,

,

" "

"

"



C1



C2

1995 1 17

(C1)

"

"

(C2)

1.4 500 "

"

500

(

)

1997

2 2 2 ,

"

"

,

"

"



D-3



D-4

(D-3)

" "

(D-4)

500

"

"

(<http://www.zhengjian.org/zj/articles/2002/3/27/14147.html>)

2 Placebo Nocebo

Prozac

Dr. Leonard Cobb
(Internal ~~Minor~~ Li gati on) angi na)

"Food and Drug Administration (FDA)"
20% 25%

placebo
<http://www.zhengji.cn.org/zj/articles/2001/2/9/8236.html>

3. " " --

[] " "

" "

1000-2000


A B 16 A4: A3B: A2B2: AB3: B4=1: 4: 6: 4: 1

A/B A3B 15%

[1]

A+B (1) AAAA+ (4) AAAB+ (6) A2B2+ (4) AB3B+(1) BBBB + linear polymers etc.

A 3 6- () B 4- -3 6- ()
A3B A3B
A3B 1 4- -2- -8 11 15 18 22 25-
4. 5% [2]



A, B

1. 5%

350mg A

B

1-4

5-8

350mg A

B

1-4

5-8

编号	反应物 之间的 摩尔比	内导物	内导物 的 量 分 比 (%)	反应 温 度 (°C)	反应 时 间 (hr)	空白实验中目标产物 量 (mg)			内导物实验中目标产 物量 (mg)			目标 产物 产 率 分 比 (%)
						A4	A3B	A2C2	A4	A3B	A2C2	
1	3A:1B	A3B	0.67	65	40	36	11	-	50	31	-	182
2	3A:1B	A3B	0.29	60	18	27	27	-	57	58	-	115
3	3A:3B	A3B	0.92	63	12	34	30	-	35	78	-	160
4	3A:1B	A3B	0.67	70	19	20	9	-	20	20	-	122
5	3A:3C	A3C*	0.71	70	36	80	90	-	80	100	-	100
6	3A:3C	A4	1.4	72	38	80	80	-	160	80	-	100
7	3A:3C	A2C2	1.4	72	38	80	80	60	80	80	120	100
8	3A:3C*	A2C2*	0.67	70	72	5	0	0	80	90	250	2
9	3A:1.5C	A3C*	0.88	82	20	30	72	-	30	79	-	8

*

40

10

90

350

3 6-

4 -3 6-

4

1

/

10 1

[2]

1. 1

1%

125%

" "

B 4- -3 6-


() C 3 6- -4-
5

A3C

6 A4 A4

7 A2C2 A2C2
A2C2

9 c' A3C A3C 2 " " A3C
3 6- -3- 3 6- -4-
5 " " A3C



AAAC AAAD

A4 " " A4 A3B
A3B A3B

8

" "

" " " "

" [3] " " " "

20
A4 A3B A4 A3B A4 A3B
" "

Q. 29-1. 4%

A4, A3B, A3C A2C2

A4

A3B

" "

A4, A3B, A3C A2C2

" "

" "

" "

[4]

"

" "

"

"

"

" " [5]

" " [6]

" " [7]

[8]

[9]

[10]

[11]

[12]

1. Tomás Torres, J. porphyrins phthalocyanines 2000, 4, 325
2. M. J. Cook, M. J. Heeney, Chem. Eur. J. 2000, 6, 3958-3967
3. D. philp, Chem. Soc. Rev. 2000, 29, 141-152
4. ISBN 962-8143-02-6
5. 1978
6. http://news.bbc.co.uk/1/eng/ish/sci/tech/newsid_1332000/1332368.stm
7. a. <http://www.pureinsight.org/sci/sci/eng/newscontent.asp?ID=10528>
b. <http://www.pureinsight.org/sci/sci/eng/newscontent.asp?ID=10535>
- c. Denton, Michael, Evolution: A Theory in Crisis, London, 1985
- d. <http://www.alternativescience.com/darwinism.htm>
8. <http://www.pureinsight.org/sci/sci/eng/newscontent.asp?ID=10233>
9. <http://www.clearwisdom.net/en/articles/2000/5/18/9001.htm>
10. a. Peter Tompkins, Christopher O. Bird, The secret life of plants
b. Cleve Backster, Evidence of a Primary Perception in Plant Life, International Journal of Parapsychology, vol. 10, no. 4, Winter 1968, P. 329-348
11. Dick Stephen, Past-life Therapy in Action
12. <http://www.zhengjian.org/zj/articles/2001/2/1/8092.htm>
13. " " --

<http://www.zhengjian.org/zj/articles/2002/3/24/14056.htm>

4.1

1

-- 1 4 (The Nun Study) Dr. Snowdon

.
. .

OVERRI DE

4.2

Dr. van Lommel (1)

Near-death Experience, NDE,
)

NDE

NDE

NDE

NDE

NDE

NDE

van Lommel

NDE

" NDE

"

NDE

NDE

NDE

NDE

NDE

NDE

NDE

--

(2)

4.3

--

Dr. Lobo

219

(26-46)
- 1999)

Cha

(1998

Dr. Lobo

(3)

150

Krucoff

Duke

5

Dr.

(4)

1. Near Death Experience in Survivors of Cardiac Arrest: A Prospective Study in the Netherlands. Pim van Lommel et al. The Lancet 2001 358.

2 : --

(<http://zhengjia.n.org/zj/articles/2002/4/4/14549.html>)

3. Journal of Reproductive Medicine (2001; 46: 781-787)
4. American Heart Journal [2001 Nov; 142(5): 760-9]

DNA

NDE

11

I.

14

"

"

"

44

1

11

14

14

11

"

"

"

" ()

http: //www bannedbook. org/

<https://goo.gl/C6xxGf>